Why Is Everyone Talking About BioNTech Stock?
_0.png?locale=de){kind=logo}
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.
A year ago, you might not have heard of BioNTech (NASDAQ: BNTX). Shares of the German biotech were trading at about $20 as it worked on investigational messenger RNA (mRNA) therapies for infectious diseases and various types of cancer. Since then, its shares have soared more than 350%, and the company has become a fixture in everyday conversation -- at least for those closely following the coronavirus vaccine race.
That's because BioNTech is the developer behind Pfizer's (NYSE: PFE) coronavirus vaccine candidate. BioNTech created the investigational product based on its mRNA technology. In March, the clinical-stage biotech company signed a co-development agreement with Pfizer, in which the two agreed to work together to bring a vaccine through trials and to market. Let's take a closer look at what's happened so far and what may be on the horizon.
Source Fool.com
